Get started
Author

Célia Salanoubat

Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
2017 · Caroline Charlier, Élodie Perrodeau, et al. · The Lancet Infectious Diseases · 611
PDF
Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories
2008 · Régis Peffault de Latour, Jean Yves Mary, et al. · Blood · 392
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
2010 · Raphael Itzykson, Sylvain Thépot, et al. · Blood · 388
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
2016 · Philippe Rousselot, Marie Magdelaine Coudé, et al. · Blood · 338
PDF
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
2010 · Sylvain Thepot, Raphael Itzykson, et al. · Blood · 160
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study
2015 · Michael Loschi, Raphael Porcher, et al. · American Journal of Hematology · 151
PDF
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
2019 · Francine Garnache-Ottou, Chrystelle Vidal, et al. · Blood Advances · 129
PDF
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
2015 · A Toma, O Kosmider, et al. · Leukemia · 129
PDF
Survival Response to B-Cell Receptor Ligation Is Restricted to Progressive Chronic Lymphocytic Leukemia Cells Irrespective of Zap70 Expression
2006 · Pierre-Antoine Deglesne, Nathalie Chevallier, et al. · Cancer Research · 103
Hyperforin, a new lead compound against the progression of cancer and leukemia?
2006 · C Quiney, C Billard, et al. · Leukemia · 71
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study
2024 · Rathana Kim, Yves Chalandon, et al. · Journal of Clinical Oncology · 57
Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency
2016 · Rémi Bertinchamp, Laurence Gérard, et al. · The Journal of Allergy and Clinical Immunology In Practice · 56
Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia
2006 · C Quiney, C Billard, et al. · Leukemia · 54
Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy
2005 · Driss Chaoui, Tahar Chakroun, et al. · Transfusion · 43
Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells
2007 · Claire Quiney, Christian Billard, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 41
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance
2010 · Philippe Rousselot, Jean Michel Cayuela, et al. · Blood · 29
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients
2023 · Timothée Bruel, Lou-Léna Vrignaud, et al. · Med · 27
PDF
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 Study
2012 · Philippe Rousselot, Marie Magdeleine Coudé, et al. · Blood · 25
Dasatinib (Sprycel®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Positive ALL: Results of the First 22 Patients Included in the EWALL-Ph-01 Trial (on Behalf of the European Working Group on Adult ALL (EWALL))
2008 · Philippe Rousselot, Jean-Michel Cayuela, et al. · Blood · 22
Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.
2009 · Sylvain Thépot, Raphael Itzykson, et al. · Blood · 21
One-day prevalence of asymptomatic carriage of toxigenic and non-toxigenic Clostridioides difficile in 10 French hospitals
2022 · A. Le Monnier, T. Candela, et al. · Journal of Hospital Infection · 20
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
2025 · David Fandrei, Jean Pegliasco, et al. · Clinical Cancer Research · 19
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents
2017 · M Duchmann, T Braun, et al. · Blood Cancer Journal · 19
PDF
Campylobacter infection in adult patients with primary antibody deficiency
2018 · Jérémie Dion, Marion Malphettes, et al. · The Journal of Allergy and Clinical Immunology In Practice · 16
PDF
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
2011 · R. Itzykson, S. Thépot, et al. · Leukemia Research · 15
Works count: 56
Citation count: 3,000
H-index: 20
I10-index: 27
Year
Topic
Type